Episurf Medical is ready to begin enrollment in the U.S. Investigational Device Exemption clinical study of theĀ EPIC-Knee EpisealerĀ® Knee.
Episurf is in contract negotiations with additional U.S. sites, and will includeĀ participants in three European countries, as well. The study allows for additional sites, should the company want to increase the number in the coming weeks.
The randomized, controlled 180-patient IDE study is the first step for Episurf to gain U.S. premarket approval for the device. The study will evaluate EpisealerĀ vs. microfracture in the treatment of focal femoral knee chondral or osteochondral lesions.
āImpressive surgical technique, innovative and highly informative pre-surgical planning tool and quick return to weight-bearing are just some of the aspects that the U.S. surgeons highlight with the EpisealerĀ technology. …If we can repeat the results from Europe, which we believe we can, this company has a bright future.āĀ said PĆ„l Ryfors, CEO.
Source: Episurf Medical
Episurf Medical is ready to begin enrollment in the U.S. Investigational Device Exemption clinical study of theĀ EPIC-Knee EpisealerĀ® Knee.
Episurf is in contract negotiations with additional U.S. sites, and will includeĀ participants in three European countries, as well. The study allows for additional sites, should the company want to increase...
Episurf Medical is ready to begin enrollment in the U.S. Investigational Device Exemption clinical study of theĀ EPIC-Knee EpisealerĀ® Knee.
Episurf is in contract negotiations with additional U.S. sites, and will includeĀ participants in three European countries, as well. The study allows for additional sites, should the company want to increase the number in the coming weeks.
The randomized, controlled 180-patient IDE study is the first step for Episurf to gain U.S. premarket approval for the device. The study will evaluate EpisealerĀ vs. microfracture in the treatment of focal femoral knee chondral or osteochondral lesions.
āImpressive surgical technique, innovative and highly informative pre-surgical planning tool and quick return to weight-bearing are just some of the aspects that the U.S. surgeons highlight with the EpisealerĀ technology. …If we can repeat the results from Europe, which we believe we can, this company has a bright future.āĀ said PĆ„l Ryfors, CEO.
Source: Episurf Medical
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.